NCT07023016View on ClinicalTrials.gov

Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

515

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions

Acute Decompensated Heart Failure (ADHF)Chronic Kidney Disease (CKD)

Interventions

DRUG

Sacubitril / Valsartan

Patients will receive sacubitril/valsartan at an initial dose of 24/26 mg Bid.

DRUG

Ramipril (ACE-inhibitor)

Patients will receive ramipril at an initial dose of 2.5 mg Bid.

Trial Locations (2)

Unknown

Cairo University Hospitals, Cairo

National Heart Institute, Cairo

All Listed Sponsors

collaborator

Cairo University

OTHER

lead

National Heart Institute, Egypt

OTHER_GOV

NCT07023016 - Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure | Biotech Hunter | Biotech Hunter